Matching articles for "Zembrace"
Comparison Table: Triptans for Migraine (online only)
View the Comparison Table: Triptans for Migraine
Med Lett Drugs Ther. 2023 Jun 12; 65(1678):e97-9 doi:10.58347/tml.2023.1678b
View the Comparison Table: Triptans for Migraine
Drugs for Migraine
An oral nonopioid analgesic is often sufficient for acute treatment of mild to moderate migraine pain without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to severe…
Med Lett Drugs Ther. 2023 Jun 12; 65(1678):89-96 doi:10.58347/tml.2023.1678a
An oral nonopioid analgesic is often sufficient for acute treatment of mild to moderate migraine pain without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to severe migraine in most patients without vascular disease. Treatment of pain when it is still mild to moderate in intensity improves headache response and reduces the risk of recurrence.
Drugs for Migraine
An oral nonopioid analgesic is often sufficient for acute treatment of mild to moderate migraine headache without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to severe…
Med Lett Drugs Ther. 2020 Oct 5; 62(1608):153-60
An oral nonopioid analgesic is often sufficient for acute treatment of mild to moderate migraine headache without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to severe migraine headache pain in most patients without vascular disease. Early treatment of pain when it is still mild to moderate in intensity improves headache response and reduces the risk of recurrence.
Lasmiditan (Reyvow) and Ubrogepant (Ubrelvy) for Acute Treatment of Migraine
Lasmiditan ( Reyvow – Lilly), an oral serotonin (5-HT 1F ) receptor agonist, and ubrogepant ( Ubrelvy – Allergan), an oral calcitonin gene-related peptide (CGRP) receptor antagonist, have been approved by…
Med Lett Drugs Ther. 2020 Mar 9; 62(1593):35-9
Lasmiditan ( Reyvow – Lilly), an oral serotonin (5-HT 1F ) receptor agonist, and ubrogepant ( Ubrelvy – Allergan), an oral calcitonin gene-related peptide (CGRP) receptor antagonist, have been approved by the FDA for acute treatment of migraine with or without aura in adults.
Comparison Table: Triptans for Migraine (online only)
View the Comparison Table: Triptans for Migraine
Med Lett Drugs Ther. 2017 Feb 13; 59(1514):e27-9
View the Comparison Table: Triptans for Migraine
